PredilifeXPAR:ALPRE -4.55%32 EBITDA Margin % is -162.48% as of Dec. 2025. GuruFocus rates XPAR:ALPRE with a GF Score™ of 32/100 and a GF Value™ of €18.98 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Predilife ranks worse than 87.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Predilife's EBITDA for the
six
months ended in Dec. 2025 was €-1.18 Mil. Predilife's Revenue for the
six
months ended in Dec. 2025 was €0.73 Mil. Therefore, Predilife's EBITDA margin for the quarter that ended in Dec. 2025 was -162.48%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Predilife EBITDA Margin % Related Terms
Predilife EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Predilife's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALPRE vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Predilife's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predilife EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Predilife's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Predilife's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Predilife (XPAR:ALPRE) has a EBITDA Margin % of -162.48% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Predilife and its competitors. According to the industry distribution chart, Predilife ranks #178 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 87.3%.
Is Predilife's EBITDA Margin % too high?
Predilife's current EBITDA Margin % is -162.48%. Based on the distribution chart, Predilife ranks #178 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Predilife has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Predilife's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Predilife ranks #178 out of 204 companies for EBITDA Margin %. This places Predilife in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Predilife and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Predilife's current EBITDA Margin % is -162.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predilife stock overvalued right now?
Based on GuruFocus' analysis, Predilife (XPAR:ALPRE) is currently considered Possible Value Trap. The stock's GF Value™ is €18.98, compared to a current price of €2.10 — trading 88.9% below its estimated fair value. The current EBITDA Margin % is -162.48%. Predilife's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Predilife (XPAR:ALPRE), the current EBITDA Margin % is -162.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Predilife (XPAR:ALPRE) Overvalued in 2026?
Based on GuruFocus' analysis, Predilife stock appears to be undervalued.
The current stock price of €2.10 is trading 88.9% below its estimated GF Value™ of €18.98.
GuruFocus considers Predilife to be Possible Value Trap.
Key valuation signals for XPAR:ALPRE:
EBITDA Margin %: -162.48%
GF Value™: €18.98 vs. price of €2.10 (88.9% below fair value)
No single metric tells the full story. See the XPAR:ALPRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Predilife SA develops solutions for predictive medicine, combining medical techniques (genetic tests, medical imaging) and mathematical models with a large amount of statistical data, which allows each individual to define their risk profile for the occurrence of various serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.
32GF Score
Get the complete analysis for XPAR:ALPRE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALPRE has been successfully added to your 
